VX-01
- Generic Name
- VX-01
A Study to Evaluate the Efficacy and Safety of Orally Administered VX-01
Phase 2
Recruiting
- Conditions
- Diabetic RetinopathyNPDR - Non Proliferative Diabetic Retinopathy
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-01-13
- Last Posted Date
- 2025-03-10
- Lead Sponsor
- Vantage Biosciences Ltd
- Target Recruit Count
- 100
- Registration Number
- NCT06770933
- Locations
- 🇺🇸
Retina-Vitreous Associates Medical Group, Beverly Hills, California, United States
🇺🇸Stanford Byers Eye Institute, Palo Alto, California, United States
🇺🇸California Retina Consultants- Santa Barbara, Santa Barbara, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath